Chemoreirradiation for recurrent salivary gland malignancies.

Journal Article

BACKGROUND AND PURPOSE: To report our experience in treating recurrent salivary gland malignancies using concurrent chemotherapy and reirradiation. MATERIALS AND METHODS: Between 1986 and 2007, 14 patients with locoregionally recurrent salivary gland cancer underwent maximal surgical resection followed by adjuvant 5-fluorouracil and hydroxyurea-based chemotherapy concurrently with 1.5Gy twice daily or 2Gy daily reirradiation. Each cycle consisted of chemoreirradiation for 5 consecutive days followed by a 9-day break. The median reirradiation dose was 66Gy (R 30-72Gy) after a mean radiation treatment interval of 48 months. RESULTS: The median follow-up for all patients was 18 months (R 2-125 months) and 41 months for survivors. The parotid gland (n=6) and minor salivary glands (n=6) were involved more commonly than the submandibular gland (n=2). Locoregional control at 1 and 3years was 72.2% and 51.6%, respectively. Actuarial overall survival at 3 and 5 years was 35.7% and 26.8%, respectively. Tracheostomies and feeding tubes were placed in 2 and 8 patients, respectively. Six patients had feeding tubes at last follow-up or death. CONCLUSIONS: Concurrent chemotherapy and reirradiation for recurrent salivary malignancies result in promising locoregional control for patients with recurrent salivary gland malignancies.

Full Text

Duke Authors

Cited Authors

  • Pederson, AW; Haraf, DJ; Blair, EA; Stenson, KM; Witt, M-E; Vokes, EE; Salama, JK

Published Date

  • June 2010

Published In

Volume / Issue

  • 95 / 3

Start / End Page

  • 308 - 311

PubMed ID

  • 20385414

Electronic International Standard Serial Number (EISSN)

  • 1879-0887

Digital Object Identifier (DOI)

  • 10.1016/j.radonc.2010.03.006


  • eng

Conference Location

  • Ireland